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GENOMICS & ETHNICITY:
USING A TOOL IN THE U.S.
ENVIRONMENTAL PROTECTION
AGENCY'S ENVIRONMENTAL

JUSTICE TOOLKIT
DAVID L. MCMURRAY, JR.*

INTRODUCTION

While a relatively new issue, environmental justice has had a major impact on
environmental law. The environmental justice movement encourages the
development of environmental laws that fairly treat persons regardless of race or
income.1 The movement is the result of disproportionate treatment of minority
groups, both real and perceived.2 Results of the movement include Environmental
Protection Agency (EPA) investigations, Executive Orders, environmental justice
infrastructure within the EPA, and most recently, the EPA's development of an
Environmental Justice Toolkit. 3 This Toolkit relies on environmental justice
assessors to consider Environmental Indicators, Health Indicators, Social
Indicators, and Economic Indicators in applying a four-phase framework to
determine whether an environmental injustice exists and, if so, its extent.4
New developments in genomics may help environmental justice assessors
apply this Toolkit. For many decades, scientists have found that a majority of
persons of different ethnicities may show a greater or lesser reaction to chemicals
or drugs than other persons. These findings came to a major head when chemical
trials of the drug BiDil encouraged the Food and Drug Administration to approve it
specifically for African American patients in June 2005. 5 With the ability to link
Copyright © 2007 by David L. McMurray, Jr..
* J.D. Candidate, 2007, University of Maryland School of Law (Baltimore, MD). B.S., Biology &
Psychology, 2002, East Tennessee State University (Johnson City, TN). The author would like to thank
Professors Rena Steinzor and Robert Percival, along with all of this Journal's staff.
1. OFFICE OF ENVTL. JUSTICE, U.S. ENVTL. PROT. AGENCY, TOOLKIT FOR ASSESSING POTENTIAL
ALLEGATIONS OF ENVIRONMENTAL INJUSTICE i (2004), available at

http://www.epa.gov/compliance/resources/policies/ej/ej-toolkit.pdf [hereinafter TOOLKIT].
2. Id.
3. Id. at ii; 4 FRANK P. GRAD, TREATISE ON ENVIRONMENTAL LAW § 9.10 (2006).
4. TOOLKIT, supra note 1,at 18-20, 26.
5. Michelle Meadows, FDA Approves Heart Drugfor Black Patients, FDA CONSUMER, Sept.-Oct.
2005, at 8, 8.
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ethnicity to drug susceptibility comes the possibility of linking ethnicity to toxin
and xenobiotic susceptibility.
This article postulates that advances in the genomics fields of
pharmacogenomics and toxicogenomics concerning ethnicity will provide the EPA
with a new and powerful tool to protect minority populations from environmental
injustices. Part I explores the history of the environmental justice movement, the
EPA's stake in this movement, and the EPA's Environmental Justice Toolkit. Part
II introduces the reader to the field of genomics, specifically to pharmacogenomics
and toxicogenomics. This part also discusses the new work being done in these
fields. Part III discusses how pharmacogenomics provides an analogy for the
impact that ethnic advances in toxicogenomics can have. This part also applies
those advances to the Environmental Justice Toolkit and discusses ethical issues
that may arise. Finally, Part IV concludes by noting that although the potential for
ethnicity-related toxicogenomics developments to impact the EPA's assessment of
environmental justice claims may be small, this victory could signal a new alliance
between toxicogenomic scientists and those populations disproportionately affected
by environmental injustices.
I.

ENVIRONMENTAL JUSTICE AND THE

EPA's

ENVIRONMENTAL JUSTICE TOOLKIT

In the early days, environmentalists ignored or did not perceive the existence
of environmental justice issues.6 However, as the environmental movement has
gained steam and environmental injustices have come to light, the environmental
justice movement has moved forward as an issue of concern to most, if not all
environmentalists. 7 This development is reflected in lawsuits brought by those
affected by environmental injustice, the EPA's research into the issue and decision
to set up an Office of Environmental Equity, President Clinton's decision to issue
an Executive Order dealing with the subject, and the subject of this article, the
EPA's "Toolkit for Assessing Potential Allegations of Environmental Injustice." In
this part, these developments are discussed, with particular focus on the
Environmental Justice Toolkit.
A.

EnvironmentalJustice: A BriefHistory and Discussion

The United States Environmental Protection Agency (EPA) defines
"environmental justice" as "the fair treatment of people of all races, cultures,
incomes, and educational levels with respect to the development, implementation,
and enforcement of environmental laws, regulations, and policies." 8 According to
the EPA, "[flair treatment implies that no population of people should be forced to
6. EDWARDO LAO RHODES, ENVIRONMENTAL JUSTICE IN AMERICA: A NEW PARADIGM 30 (2003).

7. Id. at 43-44, 53-63.
8. GRAD, supra note 3, § 9.10[l][a] (citing U.S. ENVTL. PROT. AGENCY, THE ENVIRONMENTAL
PROTECTION
AGENCY'S
ENVIRONMENTAL
JUSTICE
STRATEGY
(1995),
available at

http://www.epa.gov/compliance/resources/policies/ej/ej-strategy_

995.pdf).
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shoulder a disproportionate share of the negative environmental impacts of
pollution or environmental hazards due to lack of political or economic strength." 9
Until recently, the unequal distribution of environmental hazards and benefits
of environmental regulation had no place in the agendas of mainstream
environmental organizations.' 0 Instead, the environmental movement originally
focused on the objects of the environment-animals or land-without considering
the varying impact of environmental law and policy upon humankind.l' In addition,
mainstream environmentalists in environmental groups and the government,
consisted largely of middle- and upper-class Caucasians, while minorities and the
poor initially showed little interest in environmental issues.' 2 Thus, it comes as no
surprise that issues of race, ethnicity, and class were not among the original
concerns of mainstream environmentalists.
Today, however, environmental justice has surfaced as an important theme of
environmental policy discussion. 3 This surfacing traces its history back as far as
1967, a year that saw "one of the earliest public outcries for environmental
justice."' 14 When an eight-year-old African American girl drowned in a garbage
dump located near an elementary school in a predominately African American
neighborhood, an escalated campus protest took place at Southern Texas
University. 15 Other incidents in Houston, Texas followed, eventually leading to one
of the first class action lawsuits challenging a siting decision as a violation of the
Civil Rights Act, Bean v. Southwestern Waste Management Corp.,'6 which set the
stage for other lawsuits challenging siting decisions. 7 In the early 1980s, protests
became more unified and eventually established environmental justice as an issue
of national concern, perpetuating studies on the issue and focusing national
attention.18
B.

The EPA's Role in EnvironmentalInjustice Assessment: A Toolkit for
Assessing PotentialAllegations of Environmental Injustice

Although history has shown environmental justice being championed by some
community organizations and individuals, both the legitimacy' of environmental
justice as a problem and the community's role in its resolution have been called

9. RHODES, supra note 6, at 19.
10. Id. at30.
11.Id. at30-31.
12. Id.at31.
13. Id. at43-44.
14. GRAD,supra note 3,§ 9.10[1][b].
15. Id.
16. 482 F.Supp. 673 (S.D.Tex. 1979).
17. GRAD,supra note 3,§ 9.10[l][b].
18. Id. (citing Robert Bullard, Race and EnvironmentalJustice in the United States, 18 YALE J.

INT'L L.319 (1993)).
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into question. 19 Yet, social, economic, health, and technological factors pushed
environmental justice into the limelight as an important policy issue. 20 As a result,
EPA Administrator William K. Reilly established the Environmental Equity
Workshop in 1990 to study evidence showing that minority and low-income
communities were disproportionately affected by environmental hazards. 2 1 The
Workshop's report, published in 1992, concluded that minorities experience
disproportionately greater exposure to environmental pollutants.22 In the same year,
the EPA created the Office of Environmental Equity to oversee environmental
justice at the EPA.23 Shortly thereafter, in 1994, the EPA created a three-tiered
environmental justice infrastructure to (1) work with the Office of Environmental
Equity in ensuring that environmental justice issues are considered; (2) cross media
policy development and multi-media environmental justice project coordination;
24
and (3) provide education and outreach on environmental justice information.
Today, many groups, both within and outside of the EPA, consider and
attempt to neutralize environmental justice issues. While the aforementioned
Office of Environmental Equity came first, in February of 1994 President Clinton
issued the first general federal initiative to address concerns for environmental
justice. 26 Executive Order No. 12898, entitled "Federal Actions to Address
Environmental Justice in Minority Populations and Low-Income Populations,"
requires all federal agencies to make environmental justice part of their mission by
identifying and addressing, as appropriate, "disproportionately high and adverse
human health or environmental effects of its programs, policies, and activities on
minority populations and low-income populations., 27 According to a Presidential
Memorandum released on the same day, the Executive Order is "intended to
promote nondiscrimination in Federal programs substantially affecting human
health and the environment" through public participation and access to information,
to modify existing laws, such as the National Environmental Policy Act of 1969
(NEPA), to consider environmental justice issues and effects, to provide
opportunities for minority and low-income communities to be heard on the issues,
and to address mitigation measures. 28 In response, the EPA established an Inter-

19. RHODES, supra note 6, at 43-44.

20. Id. at 51-54.
21. GRAD, supra note 3, § 9.1 0[1 ][b]; see Julie A. Roque, EnvironmentalEquity: Reducing Riskfor
All Communities, ENV'T, June 1993, at 25, 25-26.
22. U.S. ENVTL. PROT.
COMMUNITIES 12 (1992).

AGENCY,

ENVIRONMENTAL

EQUITY:

REDUCING

RISK FOR

ALL

23. GRAD, supranote 3, § 9.10[li][b]; see Roque, supra note 21, at 27.
24. GRAD, supra note 3, § 9.10[1][b].
25. The Interagency Working Group on Environmental Justice, as well as each federal agency, was
required to address environmental justice issues by the President. Exec. Order No. 12,898, 59 Fed. Reg.
7,629 (Feb. 16, 1994).
26. GRAD, supranote 3, § 9.10[4][c).
27. Exec. Order No. 12,898, 59 Fed. Reg. 7,629 (Feb. 16, 1994).
28. Memorandum on Environmental Justice, 30 WEEKLY COMP. PRES. DOc. 279 (Feb. 11,1994).
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Agency Working Group to implement the Order among federal agencies,
developed an Environmental Justice Strategy and a plan to implement its goals, and
set up a diverse Federal Advisory Committee to make recommendations on
environmental justice issues. 29
More recently, the EPA took steps toward fighting environmental injustice by
developing a "Toolkit for Assessing Potential Allegations of Environmental
Injustice., 30 The EPA developed the Toolkit to help its Environmental Justice
Coordinators assess the environmental and human health concerns raised by
communities and other stakeholders, as well as to promote national consistency in
the way environmental justice concepts are "understood and addressed" by the
Agency.31 Using the Toolkit, Agency officials can conduct preliminary assessments
of environmental justice allegations.32 EPA Assessment Teams consider the
following:
Whether individuals, certain neighborhoods, or federally recognized
tribes suffer disproportionately adverse health or environmental effects
from pollution or other environmental hazards; [w]hether individuals,
certain neighborhoods, or federally recognized tribes suffer
disproportionate risks or exposure to environmental hazards, or suffer
disproportionately from the effects of past under-enforcement of state or
federal health or environmental laws; [w]hether individuals, certain
neighborhoods, or federally recognized tribes have been denied an
opportunity for meaningful involvement, as provided by law, in
governmental decisionmaking relating to the distribution of
environmental benefits or burdens. Such decisionmaking might involve
permit processing and compliance activities.33
In accordance with these goals, the Toolkit presents a framework for an
overall environmental justice assessment methodology to be applied on a case by
case basis. 34 The framework contains four phases: Phase 1 - Problem Formulation;
35
Phase 2 - Data Collection; Phase 3 - Assessment of the Potential for "Adverse"
Environmental and Human Health Effects; and Phase 4 - Assessment of the

29. GRAD, supra note 3, § 9.10[4][c][iii].
30. TOOLKIT, supra note 1, at ii. The Toolkit was created in 2004 and intended as a "living
document," which may be revised periodically. Id. While it is not legally binding on the EPA, states,
Indian tribes, or the regulated community, the Toolkit does provide a framework for understanding
national policy on the subject of environmental justice. Id.
31. Id. at 2, 4.
32. Id. at 2. It is important to recognize that the Toolkit is not designed to assess allegations under
Title VI of the Civil Rights Act of 1964. Id.
33. Id. at 4 (citing U.S. DEP'T OF JUSTICE, GUIDANCE CONCERNING ENVIRONMENTAL JUSTICE
(1995), availableat http://www.usdoj.gov/enrd/79648environmentaljusticestrategy.pdf).
34. Id. at 15.
35. An "adverse" effect or impact is defined as including "the entire compendium of 'significant'
(as defined under the National Environmental Policy Act) individual or cumulative human health or
environmental effects or impacts which may result from a proposed project or action." Id. at 16.
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Potential for "Disproportionately High and Adverse"36 Effects or Impacts.37 These
phases may be considered in the order that each situation demands. 38 However, the
key consideration is "whether a particular community is likely to suffer from
disproportionately greater environmental effects or impacts, regardless of its
39
demographics.
Noting that the concept of environmental justice means that all people should
receive fair treatment, have equal protection, and have opportunities for
involvement in decisions affecting the environment and community health, the
Toolkit sets out a number of indicators that should be examined together to
"provide a comprehensive picture of a community's economic, social,
'
environmental, and health level status or well-being. A
These "Environmental
Justice Indicators" are divided into four categories that represent areas in which
conditions occur that cause or intensify environmental justice issues: (1)
Environmental Indicators; (2) Health Indicators; (3) Social Indicators; and (4)
Economic Indicators. 4 1 Environmental Indicators help EPA Assessment Teams
understand the potential sources of environmental stressors and the community's
proximity thereto, the relative levels of stressors to which a community is being
exposed and the ways exposure occurs, and the general physical environment in
which exposure occurs.42 Health Indicators help EPA Assessment Teams
understand the general health of community residents and their ability to cope with
environmental stressors.43 These include existing health conditions, such as
morbidity and health problems, which may indicate an exposure as well as
resistance or sensitivity to pathogens and chemicals. 44 Health Indicators may also
show whether a subset of a population has health sensitivities such'as a greater
susceptibility to toxic substances, or whether a subset of a population has had a
higher cumulative exposure.45 Social Indicators help EPA Assessment Teams
understand the socio-demographic aspects of the community. 46 Some examples are
36. A "disproportionately high and adverse effect or impact" is defined as:
[A]n adverse effect or impact that: (1) is predominately borne by any segment of the
population, including, for example, a minority population and/or a low-income population; or
(2) will be suffered by a minority population and/or low-income population and is
appreciably more severe or greater in magnitude than the adverse effect or impact that will be
suffered by a non-minority population and/or non-low-income population.
Id. at 16.
37. Id. at 18.
38. Id. at 19.
39. Id.
40. Id. at 25.
41. Id. at 27. The Toolkit notes that "a community's level of public participation and access to
environmental information can diminish or augment environmental injustices." Id. at 28.
42. Id. at 28.
43. Id. at 29.
44. Id.
45. Id.
46. Id.
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vulnerability indicators-indicators that show whether a certain subpopulation is
more vulnerable to exposure because of limited access to certain amenities, such as
hospitals, potable water, proper sewage, and public transportation, or because of
personal behavior, such as smoking.47 Other Social Indicators include community
education levels and government encouragement thereof, as well as community
participation levels.48 Finally, EPA Assessment Teams consider Economic
Indicators, which may reveal trends in a community's wealth and the community's49
dependence on the operation of a facility alleged to cause environmental injustice.
These indicators are incorporated into a four-phase assessment of the potential
impacts of proposed actions and existing impacts, to make an overall determination
of whether environmental injustice exists.5 °
As noted previously, environmental justice assessors use four phases to assess
potential environmental injustice.51 In phase one, the problem formulation phase,
EPA Assessment Teams must consider the myriad of questions and issues that
started the assessment. Environmental justice indicators are important in this
phase for evaluating who, what, where, when, and in what context the EPA is
assessing the possible injustice.53 For example, Environmental Indicators help
determine the size and breadth of the problem and determine environmental
vulnerability.54 Social .Indicators are important for assessing the reference
community's demographics, knowledge, political awareness and power, and
potential vulnerability to environmental stresses. 55 Finally, Economic Indicators are
important for assessing the potential impact of environmental injustice based on
reliance placed on the polluting industry for jobs and a community's overall
economic well-being. 56 In phase two, the data collection phase, EPA Assessment
Teams collect data on "(1) the environmental actions or entities (e.g., a facility) that
create the environmental and health effects; and (2) the community of concern
where these impacts will be manifested., 57 In part one of the data collection phase,
EPA Assessment Teams collect source of stress data about Environmental
Indicators, including the number of facilities and facility proximity.5 8 Social
Indicators, also collected at this stage, are useful to determine behavioral factors

47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.

Id. at 29-30.
Id. at 30.
Id.
Id. at 58.
See supranotes 34-39 and accompanying text.
TOOLKIT, supra note 1, at 58.
Id. at 20.
Id. at 31, 38-39.
Id. at 43-53.
Id. at 30, 53-57.
Id. at 63.
Id.
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that affect community exposure. 59 In part two of the data collection phase, EPA
Assessment Teams focus more on data collection concerning the Health, Social,
and Economic Indicators of the community of concern and a reference community,
which is used to compare the adverse effects to determine if there is a
disproportionate effect on the community at issue. 60 The Toolkit encourages data
collection that includes information on the existing health conditions of the
communities, such as mortality and morbidity, and qualitative information such as
diet and smoking.6'
Phase three of the environmental assessment, "Assessment of the Potential for
'Adverse' Environmental and Human Health Effects or Impacts," uses the data
collected during phase two of the assessment to determine "whether the stresses are
62
likely to cause adverse environmental and human health/welfare impacts.,
Environmental Indicators are important in this phase to determine whether the
environment will suffer or has suffered an adverse impact from the proposed
actions or existing situation.63 Health Indicators are important in this phase of the
analysis to determine whether the environmental stress exposure will be of a
64
sufficient magnitude to cause adverse effects on a community's health or welfare.
By examining the potential effects of stressors, as well as a population's health
status and its potential vulnerability to such stressors, EPA Assessment Teams can
create a risk assessment of the existing or prospective situation.65 Existing health
conditions indicate whether a community might be more sensitive to stresses than
other communities. 66 "People with poor or compromised health status, whether
from exposure to environmental contaminants, genetics . . . , poor nutrition,

obesity, smoking, or abuse of alcohol or drugs, can be less resistant to infections..
. and less capable of detoxifying contaminants absorbed into their systems... than
people in better health., 67 A study of potential effects or impacts from stressors
under consideration represents the prospective health risk assessment.68 It would
compare "likely contaminant exposure concentrations and intake with information
on the toxicity of the contaminants. 69 Specifically, this assessment would,
[C]ompare the available indicators of exposure to readily available
information on the toxicity of the contaminants (e.g., from IRIS) .. .
identifly] toxicity-weighted emissions that may be associated with

59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.

Id.
Id. at 64.
Id. at 64-65.
Id. at 66.
Id. at 66-67.
Id. at 68.
Id.
Id.
Id.
Id.
Id.
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significant risks . . . . [and compare] measures or estimates of the
concentrations of some contaminants in environmental media .. with
chemical-specific environmental quality benchmarks ...[or] risks to the
community of concern ...with risks to the reference community by
comparing the indicators of exposure to the same contaminant for the
two communities.7 °
Alternatively, when a stressor already exists, environmental justice indicators
are less useful because these indicators do not reveal cause-and-effect
relationships. 71 Thus, further examination would be needed to show that pollutiongenerating facilities are contributing to environmental stressors causing health
effects.72 Initially, retrospective analyses of possible environmental injustices can
be based on whether or not the potential sources could have caused the effects.73
This assessment requires the postulation of two questions: (1) "Could the
population be exposed at high levels or levels exceeding toxicity benchmarks?" and
(2) "Are the observed health effects in the community consistent with the effects
that are known to be caused by the contaminants at issue?' 74 If both of these
questions are answered affirmatively, the EPA Assessment Team will additionally
assess evidence that particular sources of contaminants are causing adverse health
effects in the community, including whether other sources are not causing or
contributing to the effects, whether the effects began to occur when the facility
began operation or began dumping toxins in the environment, and whether a
stressor-response relationship can be demonstrated.75
The final phase, "Assessment of the Potential for 'Disproportionately High
and Adverse' Effects or Impacts," is reached when the EPA Assessment Team
ascertains that it cannot be certain that there are negligible risks of adverse effects
on the community.76 This final phase of analysis determines whether a "segment of
the population, including a minority population" inequitably bears an adverse effect
or impact, or whether a minority or low income population suffers more severely or
in greater magnitude than a non-minority or low-income population.77 To make this
determination, the EPA Assessment Team collects data about environmental justice
indicators and compares the community of concern with the reference
community. 78 Finally, the EPA Assessment Team may conduct a quantitative

70.
71.
72.
73.
74.
75.
76.
77.
78.

Id. at68-69.
Id.at69.
Id.at70.
Id.
Id.
Id.
Id. at70-71.
Id. at71.
Id.
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comparison to see if there are statistically significant differences between the two
groups in one or more measures of risk.79
II.

GENOMICS:

A

BRIEF INTRODUCTION AND DISCUSSION OF

PHARMACOGENOMICS AND TOXICOGENOMICS

For thousands of years, humans have known that heredity and relative health
are intertwined.80 More recently, however, humans discovered the connection
between genetics and phenotype 81 and we began to apply this knowledge less than
150 years ago.82 Today, genetics, the study of single genes and their effects, and
genomics, the study of the functions and interactions of the entire genome, have
become critical to modem healthcare. 83 Two relatively new areas of study are
having an increasingly large effect 84on our knowledge of human health:
pharmacogenomics and toxicogenomics.
A.

Pharmacogenomics

Pharmacogenetics is the methodical investigation of the influence of variation
in genes (polymorphisms) on interindividual variability in biological response to
drugs. 85 The assemblage of pharmacogenetics and human genomics has resulted in
pharmacogenomics, which: means "the influence of DNA-sequence variation on the
effect of a drug. 86 Today, the terms "pharmacogenomics" and "pharmacogenetics"
are synonymous for all practical purposes.87
Inherited

differences

in

response

to

a chemical

were

observed

and

documented as long ago as 1932.88 However, pharmacogenetics and
pharmacogenomics became viable fields of study in the 1950s when genetically

79. Id.
80. Alan E. Guttmacher & Francis S. Collins, Genomic Medicine-A Primer, in GENOMIC
MEDICINE 3, 3 (Alan E. Guttmacher et al. eds., 2004) (citing 2 THE GENUINE WORKS OF HIPPOCRATES
338 (Francis Adams trans., 1886)).
81. Phenotype is defined as "[t]he clinical presentation or expression of a specific gene or genes,
environmental factors, or both." Alan E. Guttmacher et al., Glossary, in GENOMIC MEDICINE, supra note
80, at xix, xxi.
82. Guttmacher & Collins, supra note 80, at 3.
83. Id. (citing Victor A. McKusick & Frank H. Ruddle, Editorial, A New Discipline, A New Name,
A New Journal, I GENOMICS 1-2 (1987)).
84. For an exhaustive discussion of genetics, including applications of toxicogenomics to
environmental law generally, see Jamie A. Grodsky, Genetics and Environmental Law: Redefining
Public Health, 93 CAL. L. REv. 171 (2005).
85. Kurt Kesseler, Pharmacogenetics: The Effect of Inherited Genetic Variation on Drug
Disposition and Drug Response, in 21 MOLECULAR BIOLOGY IN MEDICINAL CHEMISTRY 325, 325
(Theodor Dingermann et al. eds., 2004).
86. Richard Weinshilboum, Inheritance and Drug Response, in GENOMIC MEDICINE, supra note
80, at 41, 50.
87. William E. Evans & Howard L. McLeod, Pharmacogenomics-Drug Disposition, Drug
Targets, and Side Effects, in GENOMIC MEDICINE, supra note 80, at 54, 54.
88. Kesseler, supra note 85, at 325.
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determined variations were considered to be the cause of adverse drug effects.89 In
the early 1980s, researchers clarified the role of the molecular genetic basis of
inherited differences in drug response when they began to clone and characterize
genes. 90 Since then, researchers have identified more and more genetic variations
that are associated with varying drug responses. 91 In fact, it is now estimated that
genetic variability can explain between twenty and ninety-five percent of variability
in drug disposition and effects.92
Of particular interest for purposes of this article, pharmacogenetics has shown
that discrete populations such as minority groups may react differently to various
drugs based on their genetic makeup.93 Initially, studies showed that primaquine
sensitivity, a drug-induced hemolytic anemia, occurred more frequently in African
Americans than among Caucasian Americans. 94 In another early study, almost all
persons of African and Native American descent were able to taste phenylthiourea,
while almost a third of European descendants could not.95 In both of these cases,
the differences in these populations consisted of differences in the relative
frequency of one gene, most likely as a result of the balance between advantages
and disadvantages conveyed by that gene.96
Although differences in populations were noted as early as 1962,9' "[s]tudies
of the pharmacokinetics [the process by which a drug is absorbed, distributed,
metabolized, and eliminated from the body], pharmacodynamics (concentrationresponse relationship), efficacy, and toxicity of drugs have traditionally been
conducted in primarily Caucasian populations." 98 In response to this problem, in
1988, the National Institutes of Health (NIH) issued a policy statement that NIHsupported biomedical and bio-behavioral research projects using human subjects

89. Evans & McLeod, supra note 87, at 54 (citing Werner Kalow, Familial Incidence of Low
PseudocholinesteraseLevel, 2 LANCET 576 (1956); Paul E. Carson et al., Enzymatic Deficiency in
Primaquine-Sensitive Erythrocytes, 124 Sci. 484 (1956); Hettie B. Hughes et al., Metabolism of
Isoniazid inMan as Related to the Occurrence of Peripheral Neuritis, 70 AM. REV. TUBERCULOSIS 266
(1954); David A. Price Evans et al., Genetic Control of Isoniazid Metabolism inMan, 2 BRIT. MED. J.
485 (1960)).
90. Kesseler, supranote 85, at 325-26.
91. Id.at326.
92. Evans & McLeod, supra note 87, at 54 (citing Werner Kalow et al., Hypothesis: Comparisons
of Inter- and Intra-Individual Variations Can Substitute for Twin Studies in Drug Research, 8
PHARMACOGENETiCS 283 (1998)).

93. See generally WERNER KALOW, PHARMACOGENETICS: HEREDITY AND THE RESPONSE TO
DRUGS 206-22 (1962) (describing racial differences in the response to drugs).
94. Id. at 206.
95. Id. at 120, 206.
96. Id. at 206.
97. See id. at 206-22.
98. Julie A. Johnson, Influence of Race or Ethnicity on Pharmacokinetics of Drugs, 86 J.
PHARMACEUTICAL. SCI. 1328, 1328 (1997).
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should, in the absence of a compelling excuse, include women and minorities. 99
Inclusion of minorities has increased human understanding of the racial differences
in the pharmacokinetics of drugs. A review of the literature on the subject reveals
that "pharmacokinetic processes that are biologically or biochemically mediated
have the potential to exhibit differences between racial or ethnic groups."100
Unfortunately, as this review notes, information on differences in pharmacokinetics
amongst racial and ethnic groups is only available for relatively few drugs.' 0 1 The
review postulates that the problem may be due to the low inclusion rate of ethnic
minorities in clinical drug studies or, alternatively, because ethnic minorities are
not evaluated as a separate group.' 0 2 It does not help that "[t]he FDA does not
require evaluation of kinetic, dynamic, efficacy, or toxicity data by racial or ethnic
group."' 10 3 Thus, while many, like the NIH, recognize the importance of kinetic and
response differences amongst racial groups, others, such as the FDA, fail to
respond to or capitalize on the potential of these data.
Work is being done in pharmacogenomics to remedy this problem. For
example, a recent pharmacogenomic study conducted by Yee-How Say, a faculty
member in the Department of Human Growth and Development at the University
Putra Malaysia, sought to determine the genetic effect of a gene called
angiotensinogen (AGT) on hypertension.' ° According to the study, genes account
for about thirty percent of variation in blood pressure. 10 5 Three versions out of
fifteen identified variants of the AGT gene have been reported to have a genetic
association to hypertension. 10 6 Association studies concerning linkages for the
variant studied in this case, M235T, have produced conflicting resultsspecifically, that there may or may not be linkage to various ethnic populations.' 7
Noting this variation, the scientists conducting this study sought to determine
effects in Malaysians, recognizing that "genetic diversity exists among different
ethnic populations and . . . the association in one population could not be
extrapolated to another population."' 1 8 The study found an association between the

99. Id. (citing Inclusion of Women in Study Populations,NIH GUIDE FOR GRANTS AND CONT., Jan.
15, 1988, at 2,2;Inclusion of Minorities in Study Populations,NIH GUIDE FOR GRANTS AND CONT.,
supra, at 2,2-3). Such a rationale would only be compelling ifit"shows that
inclusion isinappropriate
with respect to the health of subjects or the purpose of the research." Id.
100. Id. at 1332.
101. Id.
102. Id. at 1328.
103. Id.
104. Yee-How Say et al., Angiotensinogen M235 T Gene Variants and Its Association with Essential
Hypertension and Plasma Renin Activity in Malaysian Subjects: A Case Control Study, 5 BMC
CARDIOVASCULAR DISORDERS (2005), available at http://bmc.ub.uni-potsdam.de/1471-2261-5-7/14712261-5-7.pdf.

105.
106.
107.
108.
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Id.
Id.
Id.
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M235T polymorphism of the AGT gene and hypertension.10 9 Recognizing that the
population studied was not homogenous, because the Malaysian population
consists of different ethnic groups, the authors of the study concluded that "[tihe
T235 variant is a risk factor or possibly a potential genetics marker for
hypertension." " 0
Another study, which focused on the effects of the drug BiDil, linked the
association between race and drug effect so closely that the FDA, for the first time
ever, approved the drug for use specifically for African American patients in June
2005.11' After two previous studies suggested a benefit of BiDil when taken with
other heart medications for self-identified African American patients, but no
evidence of benefits for Caucasian patients, Dr. Anne Taylor led a study known as
the African American Heart Failure Trial, which examined 1,050 self-identified
African American patients with severe heart failure who were already being treated
with the best available therapy." 2 Dr. Taylor noted that genetics alone did not
necessarily cause the effect, suggesting that different responses to the drug may
also be associated with environmental, social, or lifestyle factors, or interactions
among all those factors.' 1 3 However, the study was conducted at more than 160
sites throughout the United States. 1 4 The BiDil treatment resulted in a forty-three
percent reduction in death, a thirty-nine percent decrease in hospitalization due to
heart failure, and a decrease in heart failure symptoms for African American
patients." 5 One hypothesis as to why BiDil works is that heart failure among
African Americans is associated with a deficit of nitric oxide, and BiDil may work
by replenishing nitric oxide in the vascular tissue." 6 However, more research is
necessary to determine precisely why the drug works."17 Furthermore, a study of
the drug's effect on other populations is warranted." 8 Regardless of the exact
mechanism, the impact of this breakthrough is enormous, considering that African
Americans between ages forty-five and sixty-four are 2.5 times more likely to die
9
from heart failure than Caucasian Americans in the same age range."
The BiDil study has raised turmoil in the medical community.12 0 "Some
experts see the approval of BiDil as a steppingstone to the goal of personalized

109.
110.
111.
112.
113.

Id.
Id.
Meadows, supra note 5, at 8-9.
Id.
at 9.
Id.

114. Id.

115. Id.

116. Id.
117. Id.

118. Id.
119. Id.
120. Gray Area for New Heart Failure Drug: Although the FDA Approved BiDil for Blacks with
Heart Failure, It May Work in Anyone, HARV. HEART LETTER (Harvard Med. Sch., Boston, Mass.),
Nov. 2005, at 1, 1 [hereinafter Gray Area].

JOURNAL OF HEALTH CARE LAW & POLICY

[VOL. 10:187

medicine, with race serving as a stand-in for genetic variations that may point the
way to safer, more effective medication use.',' 21 But, while BiDil may be the first
sanctioned race-based medicine, it likely will not be the last because, although lots
of drugs are extra effective for some people and not as effective for others, drugs
like BiDil represent a potentially profitable niche. 122 However, this does not mean
that BiDil is ineffective for any other patients, and it will likely be prescribed "offlabel" to patients regardless of their ethnicity. Despite the fact that BiDil is
recommended for African American patients, individuals who lack access to au
123
courant drug and lifestyle therapies may be prescribed the components of BiDil.
And, according to Dr. Christopher Newton-Cheh, BiDil just might work as
effectively for these individuals:
Humans across the globe share most of their genes. The American
"melting pot" has added to this commingling. "It is more likely that the
genetic variation that modifies the response to a particular drug in one
race or ethnic group is also present in others," says Dr. Christopher
If a drug does have a different average effect in
Newton-Cheh ......
individuals of a certain ancestry, that effect could just as well stem from
differences in nutrition, environment, and access to health care as from
genetics. We just don't know yet." . . . NitroMed 24 and the FDA used
race as a stand-in for nitric oxide deficiency. That's partly because
asking an individual his or her race is easy. And there aren't yet simple,
inexpensive tests for nitric oxide
production or genetic tests that might
125
BiDil.
to
response
one's
reveal
Thus, the BiDil controversy is not a simple black and white issue, in terms of
race or clarity, but may represent a real breakthrough in personalized medication
based on genomics. As one group of researchers aptly wrote,
Ideally, the specific genes that determine a pharmacogenetic response
should be tested without regard to genetic ancestry since the relevant
traits usually exist in all populations ... at different frequencies. In the
absence of a specific test, choice of optimal126drug treatment based on
'racial' assignment therefore may be justified.
A lucrative new technology associated with pharmacogenomics-microarray
chips, which allow medical personnel to scan the entire human genome for
polymorphisms relevant to drug response and susceptibility-is being developed to
help determine what genes are involved in drug response and whether those genes

121.
122.
123.
124.
125.
126.

Id.
Id.
Id. at2.
NitroMed is the patent holder for BiDil. Id. at 1.
Id. at 2.
Arno G. Motulsky & Ming Qi, Pharmacogenetics,Pharmacogenomicsand Ecogenetics, 7 J.
ZHEIJIANG U. SCI. B 169,170 (2006).
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are present. 127 Furthermore, as this technology develops, it may serve to determine
the expression of genes in a target tissue to help researchers understand the
mechanisms of drug action in a genomic context.128 Chip technology will be useful
in clarifying interindividual differences in drug response. 129 This technology will
create profound changes in treatment, including, in the near future, genotyping to
"help avert severe drug toxicity that is genetically determined but occurs only
rarely."' 130 In the alternative, the advancement of microarray chip technology and
pharmacogenomics promises to help researchers design drugs "so that they are not
subject to extreme variations that result from a few well defined
polymorphisms."' 13 1 For example, drug structures are being developed so that they
do not interact with cytochrome-450 subtype CYP2D6, a gene subtype that plays a
critical role in determining the response to several drugs, to prevent toxicity
problems for poor metabolizers.' 32 The study emphasizes that there are limitations
to the promise of pharmacogenomics that must be overcome for the furtherance of
science. 133 For example, "[t]he dynamic complexity of the human genome,
involvement of multiple genes in drug responses, and racial differences in the
prevalence of gene variants impede effective genome-wide scanning and progress
towards practical clinical applications."' 134 It is also notable that, while the
importance of gene chips is unquestionable, broad use of gene chips in clinical
practice will not occur overnight. 135 However, the value of pharmacogenomics is
the knowledge of the principles underlying genetic variability and the ability to
provide more individualized treatment.136
B.

Toxicogenomics

The term toxicogenomics describes "the application of new genomics
information and methods to toxicology studies, with the goal of advancing [human]
understanding of the mechanism of action of compounds, the response of
organisms to these exposures, and the ultimate application of contributing to the
development of more accurate risk assessment models.' ' 137 Records show that
toxicology, as a discipline, dates back as far as the eleventh or twelfth century,
127. Wolfgang Sadde, Pharmacogenetics,171 W. J. MED. 328, 331 (1999) (citing Robert F. Service,
Microchip Arrays Put DNA on the Spot, 282 Sci. 396 (1998); Bob Sinclair, Everything's Great When it
Sits on a Chip: A Bright Futurefor DNA Arrays, 13 SCIENTIST 18 (1999)).
128. Id.
129. Id.
130. Id.
131. Id.
132. Id. at 330, 331.
133. Id. at 332.
134. Id.
135. Id.
136. Id.
137. Hisham K. Hamadeh & Cynthia A. Afshari, Preface, in TOXICOGENOMICS: PRINCIPLES AND
APPLICATIONS, at xix, xix (Hisham K. Hamadeh & Cynthia A. Afshari eds., 2004).
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beginning with concern about the toxic effects of metals, such as lead and arsenic,
among other things.' 8 However, over the past several decades, toxicology has
advanced to the point of using molecular methods to determine cellular responses
to compound exposures. 139 With this advance and the recent completion of the
mapping of the human and other genomes, the field of toxicology is ready to
embrace the new discipline of toxicogenomics. 140 Toxicogenomics involves the
application of "omic" technologies to toxicology and the replacement of
burdensome testing methodology with technology that will improve understanding
factors. 14 1
of the biological basis of toxicity of drugs and other environmental
Toxicogenomics offers the promise that risk assessments will no longer need to rest
on experimental studies performed at high doses in rodents, and that scientists will
be able to gain knowledge currently lacking concerning the intrinsic toxicity for the
majority of the high production chemicals introduced into the environment during
the last half of the twentieth century. 142 This promise is one of a better
understanding of the risk of toxicity of chemicals and environmental xenobiotics
through combining recent advances in genomics and other "omics" such as
proteomics and metabolomics to evaluate "(i) the diverse structure and properties
of various chemicals; (ii) the relationship between the time of exposure, dose, and
health outcomes; (iii) the influence of genetics and behavioral factors; and (iv)
interactions between143multiple components of biological systems in development of
'
the toxic response.
Although toxicogenomics is still in its fledgling stage, work is being done to
rapidly advance it.' 44 For example, the National Institute of Environmental Health
Sciences (NIEHS) created the National Center for Toxicogenomics in 2000, and
Center investigators are currently surveying the human genome and organ systems
for toxic responses to drugs and environmental xenobiotics with the goal of
determining "whether gene, protein or metabolite expression profiles or
'signatures' can serve as markers to predict toxicity.' ' 145 Furthermore, investigators
are in the process of developing a database of chemical effects on biological
146
systems to predict toxicity and to better understand the underlying mechanisms.
This work combined with the work of others seeks to fulfill toxicogenomics's
potential "(i) to identify sources of interindividual variability in response to drugs
and environmental xenobiotics ...; (ii) to provide a database for the development

138. Kenneth Olden, Foreword, in TOxICOGENOMICS: PRINCIPLES AND APPLICATIONS, supra note
137, at xv, xv.
139. Hamadeh & Afshari, supra note 137, at xix.
140. Id.
141. Olden, supra note 138, at xv.
142. Id. at xv-xvi.
143. Id. at xvi.
144. Id. at xvii.
145. Id. at xvi.
146. Id. at xvi-xvii.
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of high-throughput and low-cost platforms for screening substances for ' toxicity;
147
and (iii) to improve the process of discovering new targets for drug action."
Studies researching links between race and toxic susceptibility in the field of
toxicogenomics are rare, if existent at all. However, researchers working through an
NIEHS-created Toxicogenomics Research Consortium at a member university, the
Massachusetts Institute of Technology (MIT), are beginning to understand some of
these connections. 148 One of these researchers, John Essigmann, who was recently
awarded Thailand's Princess Chulabhorn Gold Medal 149 for his "commitment to
and sustained support for the advancement of science in developing countries, as
well as for his selfless dedication to teaching and research," is working to
understand differential gene expression in response to Aflatoxin.' 50 Aflatoxin is a
DNA damaging agent pervasive in the environment, particularly in developing
countries.151 Exposure may cause liver toxicity and cancer. 152 However, through
continuous research, Essigmann hopes to understand "why some people are
sensitive and some are resistant, how race and gender may affect why some people
respond to therapeutic drugs and others do not, why infants and children are more
susceptible than adults, and why hepatitis confers heightened sensitivity to
aflatoxin effects. 153 While Essigmann may currently be alone in his research,
development of ethnicity-specific drugs, a toxicogenomics database, and
microarray chips are likely to spur other studies searching for the genetic effects of
ethnicity on susceptibility to toxins and xenobiotics. Thus, although
toxicogenomics is a young science, new developments such as Essigmann's are
paving the way toward a developed field that will provide insights into the effects
of ethnicity on toxic response.

III. DISCUSSION
As previously noted, the EPA's environmental justice program seeks the fair
treatment of people of diverse ethnicities. 154 As part of that program, the EPA seeks
to investigate environmental justice issues using its Environmental Justice
Toolkit. 5 5 By analogy to the field of pharmacogenomics, toxicogenomics research
147. Id. at xvii.
148. See Mary Eubanks, MIT Toxicogenomics Research Program, 113 ENVTL. HEALTH PERSP. A
234(2005).
149. The Princess Chulabhorn Gold Medal is given every five years to honor world-renowned
individuals or organizations that have provided exceptional support for the activities of the Chulabhom
Research Institute, as well as support for the advancement of science in developing countries. Elizabeth
A. Thomson, Essigmann Receives Royal Honor, MIT TECH TALK, Sept. 15, 2004, at 5, available at
http://web.mit.edu/newsoffice/2004/techtalk49-2.pdf.
150. Eubanks, supra note 148, at A 234.
151. See id.
152. Id.
153. Id. at A 235.
154. RHODES, supranote 6, at 19.
155. TOOLKIT, supra note 1,at ii.
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will likely offer major breakthroughs in human understanding of the impact of
ethnicity on susceptibility to toxins and xenobiotics within the near future. These
breakthroughs may potentially provide an advantage to those suffering from
environmental injustice by adding or modifying tools in the EPA's Environmental
Justice Toolkit. This part will first address how pharmacogenomics research and
breakthroughs are applicable to toxicogenomics and genetic differences concerning
ethnicity, before moving on to consider how these advances are applicable to the
Environmental Justice Toolkit.
A.

Applying PharmacogenomicsBreakthroughsto Toxicogenomics

Pharmacogenetics and pharmacogenomics provide, by analogy, a descriptive
analysis of how and why genomics can influence our understanding of discrete
population susceptibility to environmental toxins. Based on this analogy, within a
short time research could show that toxins and xenobiotics have differing effects
based on ethnicity. Breakthroughs in pharmacogenomics and ethnicity are
applicable to toxicogenomics and ethnicity in three ways.
First, pharmacogenomics has already shown that genetically determined
variations in response to stimuli exist based on ethnicity. 156 While there is no
indication that a vast number of drugs will have differing effects based on ethnicity,
there is evidence that some drugs will be shown to be extra effective for certain
ethnicities.157 The same must be true for toxicogenomics. Like pharmaceuticals, the
effects of toxins and xenobiotics are chemical and based on metabolism. 158 At the
root of the use of genomics in either of these fields is the study of genomic sources
of metabolic differences. 59 Thus, if one field found differences in response to
chemicals based on race, it is very likely that the other should as well. Studies
seeking to determine these differences can help toxicogenomic scientists
understand what genetic variations will lead to increased or decreased susceptibility
and the process by which environmental toxins work. As previously noted, at least
one scientist is already examining the xenobiotic aflatoxin. 60
Second, pharmacogenomics can contribute to the general knowledge of how
genomics affects chemical disposition by humans.16' Toxicogenomics, as compared

156. See supra text accompanying notes 93-126.
157. See supra text accompanying notes 111-126.
158. See Olden, supra note 138, at xvi.
159. See generally id. at xvii; Evans & McLeod, supra note 87, at 54 (discussing the importance of
considering genetics in drug response).
160. See supra text accompanying notes 148-150.
161. See, e.g., Tilo Mandry, Legal Implications of PharmacogenomicsRegarding Drug Trials, Drug
Labeling, and Genetic Testing for Drug Prescription:An InternationalApproach, 59 FOOD & DRUG L.J.
519, 519 (2004).
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to pharmacogenomics, is in its relative infancy.1 62 Furthermore, toxicogenomics
does not have the kind of financial backing that pharmacogenomics has. 163 Thus, it
stands to reason that pharmacogenomics will develop more rapidly, and that
164
toxicogenomics will benefit because both fields use "omic" technologies.
Furthermore, since pharmacogenomic scientists must study the effects of genetics
on toxicity for purposes of understanding drug disposition, toxicogenomic
165
scientists stand to benefit vicariously from advances in pharmacogenomics.
Third, toxicogenomic scientists and studies on toxicity related to ethnicity
166
stand to benefit from pharmacogenomic advances in microarray chip technology.
As previously noted, these chips allow medical personnel to scan a person's
genome for polymorphisms relevant to drug response and susceptibility. 67 In
addition, this technology could help scientists to understand gene expression in
target tissues. 168 As Sad6e's study, discussed supra, further notes, this technology
69
will help scientists avert severe drug toxicity that is genetically determined.
Finally, microarray chips will help scientists to design drugs to avoid toxic
sensitivity. 70 All of the above is equally applicable to toxicogenomics. 17 1 As
previously mentioned, these two fields work on the same mechanisms, but vary
with subject matter. 72 Accordingly, microarray chips should allow toxicogenomic
scientists to scan genomes to search for ethnic differences in toxic susceptibility. 73
Microarray chips help toxicogenomic scientists to understand how gene expression
affects chemical disposition in affected tissues. 1 74 Just as with pharmacogenomics,
these chips could help toxicogenomic scientists avert severe toxic reactions that are

162. As previously noted, pharmacogenetics and pharmacogenomics began developing in the 1950s.
Evans & McLeod, supra note 87, at 54. By contrast, toxicogenomics only began to gain speed over the
past several decades. Hamadeh & Afshari, supra note 137, at xix.
163. Race-based prescription drugs like BiDil represent, "a very profitable niche." Gray Area, supra
note 120, at 1. Thus, drug companies are likely to continue to invest money in pharmacogenomics to
further develop this niche. In contrast, toxicogenomics seeks to identify the harmful effects of pollutants
and environmental xenobiotics. See Olden, supra note 138, at xvii. Thus, while toxicogenomics research
may receive some government funding, there is no impetus for polluting industries to invest in
toxicogenomics in a similar way that there is an impetus for drug companies to invest in
pharmacogenomics.
164. See Sad~e, supra note 127, at 332; Olden, supra note 138, at xv.
165. See Sad6e, supra note 127, at 330-32.
166. Id. at 331.
167. Id.
168. Id.
169. Id.
170. Id.
171. See supratext accompanying notes 156-165.
172. See supra text accompanying notes 156-160.
173. Toxicogenomists already regularly use microarray chips to determine toxic response generally.
See Edward K. Lobenhofer et al., Progress in the Application of DNA Microarrays, 109 ENVTL.
HEALTH PERSP. 881, 886 fig.2 (2001) (illustrating the microarray image and data analysis processes for
toxicogenomic studies).
174. Id. at 885.
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ethnically determined, and could help chemical manufacturers design chemicals
that will not more severely effect different populations of persons.
Thus, pharmacogenomic advances are applicable to the toxicogenomic study
of ethnically associated risks of toxicity in at least three ways: by showing that
ethnicity may be a factor in susceptibility, by helping scientists to develop a general
understanding of the effects of ethnicity on chemical disposition, and by
developing applicable technology. 175 As pharmacogenomics and toxicogenomics
advance further, this information will be supplemented with an even better
understanding of the potential impact of these new sciences. Therefore,
toxicogenomics will likely be an important tool for the EPA in assessing
environmental justice issues.
B.

Using Toxicogenomics as a Toolfor EnvironmentalJustice Assessments

When considering an environmental justice issue, the EPA must consider
"[w]hether individuals, certain neighborhoods, or federally recognized tribes suffer
disproportionately adverse health or environmental effects from pollution or other
environmental hazards."' 176 To do so, the EPA has created a framework to conduct
environmental justice assessments. 77 This framework uses indicators to assess
environmental justice problems in four phases.1 78 As will be discussed in this part,
advances in toxicogenomics concerning ethnic susceptibility to toxins can have an
impact on several of the indicators in this assessment, and on the overall
implementation of the four phase framework.
1. Effects of Toxicogenomics Advances with Regard to Ethnicity on
EnvironmentalJustice Indicators
Environmental justice indicators are intended to help Environmental Justice
Assessment Teams get the "big picture" of a community's economic, social,
environmental, and health level status, or well-being.' 79 Indicators are divided into
four categories: Environmental, Health, Social, and Economic.' 80 Toxicogenomics
advances pertaining to ethnic susceptibility to toxins and xenobiotics will affect
how an Environmental Justice Assessment Team deals with several of these
indicators.
First, these advances will help EPA Assessment Teams understand
Environmental Indicators. As previously noted, Environmental Indicators include
potential sources of environmental stressors and proximity thereto, the relative
levels of stressors to which a community is being exposed and the ways exposure

175.
176.
177.
178.
179.
180.

See supra text accompanying notes 156, 161, and 166.
See TOOLKIT, supranote 1, at 4.
Id. at 15.
Id. at 18.
Id. at 25.
Id. at 27-30.
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occurs, and the physical environment in which exposure occurs. 18 1 These potential
sources can be hard to identify because the effects and interactions of various
chemicals are little understood. 182 Furthermore, the severity of a toxic exposure
varies with proximity, leading to prolonged exposure before any outward signs of
toxicity become available. 183 However, with ethnicity-related advances in
toxicogenomics, such as the availability of information on whether a particular
ethnicity is more greatly affected by a toxin or xenobiotic, or information on how
chemicals are metabolized based on genomics, EPA Assessment Teams will be
able to better identify the chemicals that are at work, and how far away those
chemicals are. 184 Thus, advances in toxicogenomics concerning ethnicity should be
useful to Assessment Teams in their effort to identify environmental indicators.
Second, toxicogenomics advances related to ethnic susceptibility will help
EPA Assessment Teams assess Health Indicators. As previously noted, Health
Indicators allow Assessment Teams to understand the general health of a
community and their ability to cope with stressors.185 These indicators are also used
to determine whether a subset of a population has certain health sensitivities, such
as greater susceptibility to toxic substances.' 86 Because toxicogenomics
assessments of ethnic susceptibility to toxins would be the primary reason for such
research, EPA Assessment Teams would stand to greatly benefit from
toxicogenomics advances of this kind. Knowledge of ethnic susceptibility could be
used to determine whether a population was suffering from disproportionate harm
or even whether a population had a higher potential to be at risk. Because of this
ability, an EPA Assessment Team could proactively prevent the production of
toxins and xenobiotics around susceptible communities. Thus, Assessment Team's
use of Health Indicators would greatly benefit from advances in toxicogenomics
concerning ethnicity.
Finally, toxicogenomics advances concerning ethnicity will impact
Environmental Justice Assessment Teams' understanding of Social Indicators. If
Assessment Teams know about ethnic susceptibility to a particular toxin, it will
better help them understand the impact of vulnerability indicators such as proximity

181.
182.
183.
184.

Id. at 28.
Id. at 33-34.
Id. at 63-64, 68.
See COMM. ON
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RISK ASSESSMENT OF ENVTL. CHEMICALS,
TOXICOGENOMIC

NAT'L RESEARCH

COUNCIL OF THE NAT'L ACADS.,

TECHNOLOGIES AND RISK ASSESSMENT OF ENVIRONMENTAL
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A

WORKSHOP SUMMARY 28-29 (2005) (noting that microarray patterns as a result of toxic exposure may
change depending on whether the exposure was low, medium, or high); Mark Toraason et al., Applying
New Biotechnologies to the Study of Occupational Cancer-A Workshop Summary, 112 ENVTL.
HEALTH PERSP. 413, 414 (2004) (noting that toxicogenomics can produce biomarkers to show that a
toxic exposure has occurred).
185. See TOOLKIT, supra note 1, at 29.
186. Id.
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and access to hospital care. 187 With increased susceptibility and decreased access to
medical care, a population would be more vulnerable to environmental toxins than
in the absence of either.18 8 Other Social Indicators will also be impacted.5 9 If a
particular ethnic community is more susceptible to a particular toxin, with time,
they are likely to be educated about that susceptibility. 190 Thus, when a
manufacturer that produces a particular toxin is sited close by, these communities
are more likely to participate in the political process to fight that siting. 191 Thus,
social factors will be impacted by a better understanding of toxicogenomics related
to ethnicity.
2. Effects of Toxicogenomics Advances Concerning Ethnicity on
Environmental Justice Indicators as Applied Through the Environmental Justice
Toolkit's FourPhaseFramework
Environmental justice indicators create the backbone of consideration that an
Environmental Justice Assessment Team uses to work through each of the four
phases of the Environmental Justice Framework. 192 Thus, toxicogenomics advances
concerning ethnicity will also be important. As noted, four phases are used to
assess potential environmental injustice: problem formulation, data collection,
assessment of the potential adverse environmental and human health effects or
impacts, and assessment of the potential for disproportionately high and adverse
effects or impacts.193

187. A vulnerability indicator such as access to hospital care is an important demographic of a
susceptible population because it indicates that the population is more vulnerable to exposure. Id. Access
to hospital care is an important consideration because it indicates a population's ability to offset impacts
of exposure. Id.
188. See Paul J. Nietert et al., Demographic and Biologic Influences on Survival in Whites and
Blacks: 40 Years of Follow-Up in the Charleston Heart Study, 5 INT'L J. FOR EQUITY HEALTH 1, 2
(2006) (citing INSTITUTE OF MEDICINE, UNEQUAL TREATMENT: CONFRONTING RACIAL AND ETHNIC
DISPARITIES IN HEALTH CARE (2002); Janice E. Williams et al., Racial Disparities in CHD Mortality
From 1968-1992 in the State Economic Areas Surrounding the ARIC Study Communities, 9 ANN.
EPIDEMIOLOGY 472 (1999); Donna L. Armstrong et al., United States Coronary Mortality Trends and
Community Services Associated with OccupationalStructure,Among Blacks and Whites, 1984-1998, 58
SOC. SCI. & MED. 2349 (2004); David R. Williams, Race, Socioeconomic Status, and Health: The Added
Effects of Racism and Discrimination,896 ANN. N.Y. ACAD. SC. 173 (1999); Jeff Whittle et al., Racial
Differences in the Use of Invasive CardiovascularProcedures in the Department of Veterans Affairs
Medical System, 329 NEw ENG. J. MED. 621 (1993); A. Marshall McBean & Marian Gomick,
Differences by Race in the Rates of ProceduresPerformed in Hospitalsfor Medicare Beneficiaries, 15
HEALTH CARE FIN. REv. 77 (1994)).

189. Id. (citing Williams, supra note 188; Whittle et al., supra note 188; McBean & Gornick, supra
note 188).
190. See GRAD, supranote 3, § 9.10[3][b].
191. Id.
192. See supra text accompanying notes 30-79.
193. See supra text accompanying notes 34-39.
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In the first phase, problem formulation, toxicogenomics advances concerning
94
ethnicity will help EPA Assessment Teams consider what started an assessment.1
The problem formulation phase involves evaluating the population at potential risk,
what kind of toxin might cause that risk, the location of the risk and population, and
in what context the EPA is assessing the possible injustice.1 95 As noted, the EPA
196
assesses the Environmental and Social Indicators involved with this problem.
Thus, ethnic associations between toxins and the harms that impact those indicators
will be important for the proper characterization of the environmental justice
problem. In the second phase, the EPA collects data on the environmental actions
or entities that cause the environmental or health effects, and the community of
concern where impacts will be manifested. 197 Obviously, proper data collection
would involve a search of Health Indicators involving ethnic susceptibility to
toxins. 198 In phase three, the EPA Assessment Team considers the potential for
adverse environmental and human health effects or impacts. 199 Because an EPA
Assessment Team would have collected data about proximity, type of toxin, and
ethnic susceptibility as well as other indicators, 20 0 it will have a fuller picture to
assess, prospectively or retrospectively, the type of harm and relative seriousness of
the environmental justice issue. Finally, knowledge of different susceptibility levels
is powerfully useful in the final phase of the environmental justice assessment,
since that phase involves determining differential impacts on a segment of the
population. 0' Obviously, if one ethnic group has a higher overall susceptibility to a
toxin or xenobiotic, an EPA Assessment Team must consider this in making a
determination of whether there is an environmental injustice.
A full airing of the issues at stake in considering the potential for ethnic
advances in toxicogenomics on environmental justice assessments requires that
ethical issues be considered. As Sandra Soo-Jin Lee notes in her article, Paradoxes
of Difference, "if we are all the same, why do we continue to search for the ways in
which we differ from one another? '' 20 2 Lee notes that although we are 99.9 percent
the same, "there is increasing interest in identifying the relatively small percentage
difference that distinguishes individuals. 20 3 As Lee notes, "[a]t stake are issues of
power and trust, and the question of whether new genetic technologies will close

194. TOOLKIT, supranote 1,at 58.
195. Id.
196. Id. at 28, 29-30.
197. Id. at 63.
198. See id. at 65 (recommending that data be collected on factors that increase community
vulnerability to stress).
199. Id. at66.
200. Id. at 63-68.
201. Id. at 71.
202. Sandra Soo-Jin Lee, Paradoxesof Difference, 2 PUB. LIBR. Sci. BIOLOGY 1263, 1263 (2004).
203. Id.
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the gaps between groups or make them wider." 2°4 Others argue that ethnicity is
merely being used as a stand in for individual genetic variability in
pharmacogenomics advances.2 °5 While this may be true, from the point of view of
an environmental justice advocate it should not matter. Since environmental justice
advocates are concerned that populations rather than individuals may suffer
disproportionate harms based on their ethnicity, 20 6 it is actually preferable to make
generalizations about adverse exposures. Rather than opening gaps between races,
toxicogenomics as applied to environmental justice assessments stands to help
close gaps between races. The reason is simple: it provides a small tool for those
fighting environmental injustice.
IV. A REAL

WORLD HYPOTHETICAL APPLICATION

A.

The Background

The question then becomes in what situations is the public health of one
ethnic group so disproportionately threatened that environmental justice advocates
can call upon toxicogenomics in the context of the Environmental Justice Toolkit to
make positive changes for a threatened community? An obvious example is the
siting of any major pollution emitter.207 Within that example lies a less obvious
paradigm-the production of hot spots through local, state, or federal emissions
trading programs.
Emissions trading programs have found a broad following among economists,
industry, and some environmental groups as an alternative means of regulating
industry that is market based and does not rely on command and control
techniques. 20 8 The main features of such programs are an emissions cap, "the total
amount of pollution that sources can emit," and allowances or credits that provide
for the holder to discharge a certain amount of pollution. 20 9 These allowances may
be freely traded within an industry.210 Over time, the emissions cap is reduced, thus
lessening the overall number of allowances. 211 The idea is that free trading of
204. Id. at 1264.
205. See supra text accompanying notes 120-126.
206. TOOLKIT, supra note 1, at i.
207. See, e.g., Rena I. Steinzor, Toward Better Bubbles and FutureLives: A ProgressiveResponse to
the ConservativeAgenda for Reforming Environmental Law, 32 ENvTL. L. REP. 11421, 11430 (2002);
see also ROBERT V. PERCIVAL ET AL., ENVIRONMENTAL REGULATION: LAW, SCIENCE, AND POLICY 1519 (5th ed. 2006) (discussing generally whether environmental justice victims come to areas where
major polluters are sited or whether major polluters tend to site near victims).
208. See
U.S.
Envtl.
Prot.
Agency,
Clear
Skies
Cap
and
Trade
Basics,
http://epa.gov/air/clearskies/captrade.html (last visited Dec. 5, 2006) [hereinafter Clear Skies Cap and
Trade];
Rena
Steinzor,
Ctr. for
Progressive
Reform,
Emissions Trading
(2005),
http://www.progressiveregulation.org/perspectives/emissions.cfm.
209. Clear Skies Cap and Trade Basics, supra note 208.
210. Id.
211. Id.
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emissions "rewards companies that discover better ways to reduce emissions by
allowing them to sell unneeded allowances in the market," allows companies that
cannot reduce emissions to buy additional allowances, and puts businesses in the
position of determining the cheapest way to comply with regulations. 212 Critics

raise many concerns about the use of emissions trading programs.2 3 Of great
importance here, "[t]rading schemes have proved so vulnerable to abuse that they
have resulted in absolutely unacceptable concentrations of life-threatening
pollutants in areas where large numbers of people of color live. 21 4 These
concentrations, known as "hot spots," are particularly dangerous when trading
schemes are applied to toxics. 215 In addition, they may represent a major

environmental justice issue.
One such trading program raised environmental justice issues in the
jurisdiction of the South Coast Air Quality Management District (SCAQMD), a
sophisticated regulatory agency in the heart of a major pollution area-Los
Angeles, California.2 16 The trading program, known as Rule 1610, or the "car
scrapping program," "allow[ed] stationary source polluters (such as factories and
refineries) to avoid installing expensive pollution control equipment if they
purchase[d] pollution credits generated by destroying old, high-polluting cars., 217
The major environmental justice issue occurred because four oil companies began
purchasing most of the emission credits. 1 8 These companies sought to avoid
installing equipment to avoid the release of toxic gases, such as benzene, that
escape during oil tanker loading at their marine terminals.1 9 In the process, an
212. Id.
213. Aside from environmental justice issues, critics also raise ethical problems with the idea that a
value can be placed on the "public interest in natural resources." Steinzor, supra note 207, at 11426.
This problem centers around the distaste associated with turning the right to pollute into a commodity,
thus removing the social stigma normally associated with it. Richard Toshiyuki Drury et al., Pollution
Trading and Environmental Injustice: Los Angeles' Failed Experiment in Air Quality Policy, 9 DUKE
ENVTL. L. & POL'Y. F. 231, 270-71 (1999).
214. Steinzor, supra note 207, at 11426.
215. Id. at 11427.
216. Drury et al., supra note 213, at 242 n.44.
217. Id. at 246. Because of the collectively high level of pollution from old cars and mobile sources
generally and the cheapness of procuring and destroying such cars, the program was planned around the
idea that high polluting stationary sources could buy and destroy the cars, reducing pollution in equal
proportions to that emitted by the source and reducing overall pollution at a lower cost than that of
installing pollution control equipment. Id. at 246-47, 247 n.60. Once destroyed, the procurer of the car
received emission credits based on projected emissions of the car had it not been destroyed. Id. at 247.
218. Id. at 252 (citing Letter from Richard Toshiyuki Drury et al., Communities for a Better
Environment, to Anne Goode, U.S. Envtl. Prot. Agency (Nov. 23, 1998) (on file with Richard Toshiyuki
Drury et al.)).
219. Id. at 252-53 (citing Shipra Bansal & Scott Kuhn, Stopping an Unfair Trade: Environmental
Justice, Pollution Trading, and Cumulative Impacts in Los Angeles, ENVTL. L. NEWS, Spring 1998, at
16, 17-18). The cancer risk associated with emissions from exposure to these toxic gases is "greater than
150 in I million for the maximum exposed individual." Id. at 253 (citing Los ANGELES COUNTY BLDG
& CONSTR. TRADES COUNCIL & THE STEAMFITTERS & PIPEFITrERS LOCAL 250, Comments on the Draft
EnvironmentalImpact Reportfor the Renewal of Unocal's Lease for Berths 148-151, in FINAL ENVTL
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overwhelmingly Latino local population was being exposed to high levels of
dangerous pollutants, while the general 22public
in Los Angeles received a slight
0
decrease in their exposure to these toxics.

B.

The HypotheticalApplication

Applying toxicogenomics to a hypothetical environmental justice assessment
of the SCAQMD trading program provides a useful context for understanding how
the science can benefit the health of a disproportionately affected Latino
population. Specifically, toxicogenomics studies could identify biomarkers of
susceptibility, biomarkers of exposure, and biomarkers of effect that could then be
used to identify the effects of the toxin on the population. 22' Biomarkers of
susceptibility represent those biomarkers related to "variations affecting absorption,
metabolism, or response to environmental agents. 222 Biomarkers of exposure help
toxicogenomists see how much of a substance the body has absorbed.223 Finally,
"[b]iomarkers of effect reflect changes in cells or tissues triggered by chemical
exposure or changes that are qualitatively or quantitatively predictive of health
impairment or potential impairment due to toxic exposure. 224 Each of these types
of biomarkers may assist environmental justice assessors in determining whether an
environmental injustice has occurred.225 Accordingly, each is discussed below in
the context of the SCAQMD trading program.
Discovery of biomarkers of toxin susceptibility related to ethnicity will be
particularly useful because these polymorphisms affect sensitivity to a toxin and
can be discovered before exposure even occurs.226 In the context of the Latino
population suffering from high emissions of toxic fumes, these studies could show
that the population suffered a higher susceptibility to cancer than the general,

IMPACT REPORT FOR BERTHS 148-151 PORT OF Los ANGELES 17, 23 (1996)). On the other hand, the

Clean Air Act establishes that a cancer risk to a maximally exposed person of greater than one hundred
in one million is significant and warrants EPA Administrator action to protect human health. Id. at 253
n.91 (citing 42 U.S.C. § 7412(f)(2)(A) (2000)).
220. Drury et

al.,

supra note 213,

at

254-55

(citing

S. COAST

AIR

QUALITY

MGMT.

DIST./CALIFORNIA STATE UNIV. FULLERTON FOUND., THE DISTRIBUTION OF CURRENT AND FUTURE
EXPOSURE TO OZONE, FINE PARTICULATE MATTER, CARBON MONOXIDE, AND NITROGEN DIOXIDE
AMONG DEMOGRAPHIC GROUPS IN THE SOUTH COAST AIR BASIN, FINAL REPORT 5 (1993)).

221. Grodsky, supra note 84, at 183-87, 196-98. Grodsky notes that discovery of susceptibility
biomarkers is usually associated with toxicogenetics, while discovery of biomarkers of exposure and
effect are usually associated with toxicogenomics. Id. at 191-94. For purposes of this paper,
toxicogenetics is enveloped in the discussion of toxicogenomics.
222. Id. at 183.
223. Id. at 185.
224. Id. at 186 (citations omitted).
225. See supra text accompanying notes 180-184.
226. Grodsky, supra note 84, at 183-84. It is important to note that "[s]usceptibility genes are
'neither necessary nor sufficient to cause disease. They modify risk."' Id. at 184 (quoting Kenneth Olden
& Janet Guthrie, Genomics: Implicationsfor Toxicology, 473 MUTATION RES. 3, 5 (2001)).
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mixed population.227 Environmental justice assessors would consider these studies
as a viable health indicator, identifying both a potential weakness in the population
and how this weakness relates to that population's susceptibility. 228 As a result,
assessors could have made a very early determination that an environmental justice
problem existed. This could have resulted in specific guidelines for industry,
including caps on the amount of emissions units that industry could purchase in a
specific area.
Toxicogenomists' discovery of biomarkers of toxin exposure and effect will
be useful because these biomarkers will give environmental justice assessors a
direct method to measure human exposure to toxic substances. 229 Using gene chips,
toxicogenomists would measure genes and the gene products of the
230
disproportionately affected and genetically more susceptible population.
Assessors will know from these biomarkers how much exposure is in fact
occurring, and can use that understanding as an environmental indicator to
determine what action needs to be taken.2 3' Thus, prior to any symptom
manifestation, assessors will have the capability to determine whether higher
exposure rates are affecting the Latino populations and may take appropriate steps
to stop the environmental injustice, including altering the program or ending it all
together.
This example, though hypothetical in the application of toxicogenomics,
shows that toxicogenomics has real life applications in environmental justice
assessments. By using toxicogenomics to identify and measure biomarkers of
susceptibility, exposure, and effect, toxicogenomists can assist assessors in
identifying both health and environmental indicators. Thus, in cases where an
environmental justice issue may exist, such as the SCAQMD trading program,
toxicogenomics represents a new tool that can be applied to assess and remedy
environmental injustice.
CONCLUSION

As demonstrated throughout this article, new advances in genomics and
ethnicity may provide the EPA with a new and powerful tool to protect minority
populations from environmental injustice. As discussed, toxicogenomics can use
advances in pharmacogenomics, and make advances of its own that will

227. For example, the risk of cancer for maximally exposed Latinos might be 300 persons in 1
million rather than the general population's "greater than 150 in I million for the maximum exposed
individual." Drury et al., supra note 213, at 253 (citing LOS ANGELES COUNTY BLDG & CONSTR.
TRADES COUNCIL & THE STEAMFITrERS & PIPEFITTERS LOCAL 250, Comments on the Draft
Environmental Impact Report for the Renewal of Unocal's Lease for Berths 148-151, in FINAL
ENVIRONMENTAL IMPACT REPORT FOR BERTHS 148-151 PORT OF Los ANGELES 17, 23 (1996)).
228. TOOLKIT, supra note 1, at 29.

229. Grodsky, supra note 84, at 185-87.
230. Id. at 185-86, 195-96.
231. See TOOLKIT, supra note 1, at 28.
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fundamentally change how Environmental Justice Assessment Teams use
indicators in the four phase assessment framework and determine whether an
environmental injustice does, could, or will exist.23 2 Admittedly, genomics is
unlikely to significantly change the outcome of EPA's assessment of environmental
justice issues, but environmental justice advocates can use genomics to make
incremental improvements to the way that injustice problems are addressed. As
Karl Weick, a psychologist from Cornell University, once noted,
Once a small win has been accomplished, forces are set in motion that
favor another small win. When a solution is put in place, the next
solvable problem often becomes more visible. This occurs because new
allies bring new solutions with them and old opponents change their
habits. Additional resources also flow toward winners, which means that
slightly larger wins can be attempted.233
With new allies in the fields of toxicogenomics and pharmacogenomics,
perhaps those who are disproportionately affected by environmental harm can gain
new wins.

232. Supra text accompanying notes 156-206.
233. Karl E. Weick, Small Wins: Redefining the Scale of Social Problems, 39 AM. PSYCHOLOGIST
40,43 (1984).

